Clinical Scorecard: Inflammatory and Epigenetic Adaptations Driven by Endocrine Factors as a Proposed Mechanism of Radioresistance in Prostate Cancer Exposed to Endocrine Therapies: A Translational Perspective

At a Glance

Key Highlights

• Endocrine therapy may initially impair AR-dependent DNA damage response signaling.
• Sustained endocrine pressure can promote adaptive inflammatory signaling and epigenetic remodeling.
• Adaptive inflammatory activation may lead to radioresistance in prostate cancer.
• Serial biomarker profiling may better identify emerging resistance than baseline-only assessments.

Guideline-Based Recommendations

Diagnosis

• Consider the role of AR signaling and inflammatory markers in assessing prostate cancer.

Management

• Utilize endocrine therapies in conjunction with radiotherapy for high-risk prostate cancer.

Monitoring & Follow-up

• Monitor for adaptive inflammatory responses and epigenetic changes during treatment.

Risks

• Be aware of potential radioresistance due to inflammatory and epigenetic adaptations.

Patient & Prescribing Data

Patients undergoing endocrine therapy and radiotherapy for prostate cancer

Endocrine therapy may have a dynamic effect on radiosensitivity over time.

Clinical Best Practices

• Integrate assessment of inflammatory and epigenetic markers in treatment planning.
• Consider the timing of endocrine therapy relative to radiotherapy for optimal outcomes.

Related Resources & Content

• Prostate Cancer Statistics
• Androgen Receptor and DNA Repair
• Inflammation and Cancer